Clinicopathological and molecular predictors of [ 18 F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.

Antonio LlombartAleix PratJosé Manuel Pérez-GarcíaJosé MateosTomás PascualSantiago Escrivà-de-RomaniAgostina StradellaManuel Ruiz-BorregoBegoña Bermejo de Las HerasMarleen KeyaertsPatricia GalvanFara Brasó-MaristanyJuan José García-MosqueraThomas GuiotMaría GionMiguel Sampayo-CorderoSerena Di CosimoJhudit Pérez-EscuredoManuel Atienza de FrutosJavier CortésGeraldine Gebhart

Published in: European journal of nuclear medicine and molecular imaging (2024)

Clinicaltrials.gov; NCT03161353; registration date: May 15, 2017.

Keyphrases

early breast cancer
phase iii
pet ct
phase ii
positron emission tomography
pet imaging
open label
double blind
clinical trial
placebo controlled
study protocol
computed tomography
loop mediated isothermal amplification
label free
real time pcr
single molecule
randomized controlled trial